Feed RDY
RD

Dr. Reddy's Laboratories

RDY · NYSE

$12.41 +1.80% (+$0.22)
1M +1.47%
Market Cap ₹990.3B
P/E Ratio 29.86x
Div. Yield 0.67%
ROE 8.94%

Bulios Fair Price

$12.41

0.0% downside

Current Price

$12.41

Undervalued Fair Value Overvalued

According to Bulios Fair Price, RDY is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
5/9
Valuation
27 /100
Expensive
P/E 29.86x
EV/EBITDA 18.90x
P/S 2.98x
Growth
86 /100
Growing
EPS growth 33.72%
Rev. growth 14.94%
FCF growth 9.92%
Profitability
57 /100
Moderate
Gross margin 50.15%
Net margin 9.96%
Op. margin 10.57%
Quality
40 /100
Average
ROIC 5.83%
ROE 8.94%
ROA 5.77%
Debt
91 /100
Low
Debt/Equity 0.19x
Current ratio 1.90x
Int. coverage 9.50x
Stability
61 /100
Moderate
Beta 0.25x
Rev. volatility 1.55%
EPS volatility 46.77%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RDY
Online

About the company

Dr. Reddy's Laboratories Limited (RDY) is an Indian pharmaceutical company specializing in the manufacturing and distribution of a wide range of medicines and generic pharmaceutical products. The company focuses on developing and producing high-quality and affordable medications for patients worldwide. Dr. Reddy's Laboratories has an extensive portfolio of products, including medicines for various therapeutic areas, such as cardiovascular, gastrointestinal, oncology, neurological, and other indications. The company is one of the leading generic pharmaceutical companies and has a strong global presence. Dr. Reddy's Laboratories invests in research and development of new pharmaceutical products and continuously expands its portfolio. Its medications comply with strict quality standards and regulations, making it a trustworthy partner for healthcare institutions, physicians, and patients. Investing in shares of Dr. Reddy's Laboratories Limited (RDY) could present an intriguing opportunity for those who believe in the growing demand for affordable and high-quality generic medicines and the long-term potential of the pharmaceutical industry.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Erez Israeli

Employees

27,527

Headquarters

Hyderabad

Upcoming events

23 OCT

Earnings

Upcoming earnings report

31d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.